公开(公告)号：AT207515T

公开(公告)日：2001-11-15

申请号：AT97103860

申请日：1997-03-07

Applicant: BASF AG

Inventor： LUEDDECKE ERIK ,  SCHWEIKERT LONI

IPC: A23K1/00 ,  A23K1/16 ,  A23L1/275 ,  A23L2/58 ,  A23L5/44 ,  A61K9/10 ,  A61K47/24 ,  C09B61/00 ,  C09B67/46 ,  C09K23/00

Abstract: The preparation of a finely-divided carotinoid or retinoid suspension comprises dissolving the material in a volatile water-miscible organic solvent at 50-250 degrees C (optionally under increased pressure) within 10 seconds and then immediately mixing the solution with an aqueous medium at 0-90 degrees C in the absence of protective colloid and in the presence of a physiologically acceptable emulsifier. Also claimed is a finely-divided carotinoid or retinoid suspension free from protective colloid contains an emulsifier chosen from lecithin, mono-, di- or tri-glycerides of aliphatic (optionally acetylated) polycarboxylic acids (eg citric or tartaric acid) or ascorbyl palmitate.

公开(公告)号：AU782556B2

公开(公告)日：2005-08-11

申请号：AU7050101

申请日：2001-05-03

Applicant: BASF AG

Inventor： HAHNLEIN WOLFGANG ,  KRAMER KLAUS ,  HASSELWANDER OLIVER ,  SCHWEIKERT LONI

IPC: A23L1/30 ,  A23C9/158 ,  A23K1/16 ,  A23L1/305 ,  A23L2/52 ,  A23L33/00 ,  A23L33/15 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/7076 ,  A61K31/714 ,  A61P9/00 ,  A61P25/00 ,  C07D475/04 ,  A23L1/302

Abstract: Compositions are proposed which comprise folic acid in combination with 5-methyltetrahydrofolic acid, and also compositions which comprise folic acid, 5-methyltetrahydrofolic acid and/or 5-methyltetrahydrofolylpolyglutamate and also comprise a dietary component and/or a nutrient preparation, and their use is also proposed.

公开(公告)号：DE50103029D1

公开(公告)日：2004-09-02

申请号：DE50103029

申请日：2001-09-11

Applicant: BASF AG

Inventor： HASSELWANDER OLIVER ,  KRAEMER KLAUS ,  BALDENIUS KAI-UWE ,  KLATT JOCHEN ,  SCHWEIKERT LONI

IPC: A61K31/381 ,  A23L1/30 ,  A61K31/00 ,  A61K31/202 ,  A61K31/385 ,  A61P3/10 ,  A61P9/10 ,  A61P13/12 ,  A61P25/02 ,  A61P27/02

Abstract: The present invention relates to the use of lipoic acid, a physiologically acceptable derivative or salt thereof and one compound of the formula I H3C-(CH2)n1-(CH=CH)n3-(CH2)n2-COOH I in which n1, n2 have, independently of one another, the value of an integer from 3 to 9, n3 has the value of an integer from 2 to 6, and the number of carbon atoms is 18, 20 or 22, a physiologically acceptable derivative or salt thereof, for nutritional supplementation, in functional foods and for therapeutic purposes in the treatment of diabetic disorders. Compositions having a corresponding active ingredient combination, and compositions in the form of commercial packs with corresponding combination products or single-drug products for combined use are also described.

公开(公告)号：CA2408401A1

公开(公告)日：2002-11-06

申请号：CA2408401

申请日：2001-05-03

Applicant: BASF AG

Inventor： HASSELWANDER OLIVER ,  SCHWEIKERT LONI ,  HAHNLEIN WOLFGANG ,  KRAMER KLAUS

IPC: A23L1/30 ,  A23C9/158 ,  A23K1/16 ,  A23L1/305 ,  A23L2/52 ,  A23L33/00 ,  A23L33/15 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/7076 ,  A61K31/714 ,  A61P9/00 ,  A61P25/00 ,  C07D475/04 ,  A23L1/302 ,  A23L1/29

Abstract: Compositions containing folic acid in combination with 5-methyltetrahydrofol ic acid are disclosed, as well as compositions containing folic acid, 5- methyltetrahydrofolic acid and/or 5-methyltetrahydrofolic acid polyglutamate and a dietary component and/or a dietary preparation and the use thereof.

公开(公告)号：DE19609538A1

公开(公告)日：1997-09-18

申请号：DE19609538

申请日：1996-03-11

Applicant: BASF AG

Inventor： LUEDDECKE ERIK ,  SCHWEIKERT LONI

IPC: A23K1/00 ,  A23K1/16 ,  A23L1/275 ,  A23L2/58 ,  A23L5/44 ,  A61K9/10 ,  A61K47/24 ,  C09B61/00 ,  C09B67/46 ,  C09K23/00 ,  B01F17/00 ,  A23L1/03

Abstract: The preparation of a finely-divided carotinoid or retinoid suspension comprises dissolving the material in a volatile water-miscible organic solvent at 50-250 degrees C (optionally under increased pressure) within 10 seconds and then immediately mixing the solution with an aqueous medium at 0-90 degrees C in the absence of protective colloid and in the presence of a physiologically acceptable emulsifier. Also claimed is a finely-divided carotinoid or retinoid suspension free from protective colloid contains an emulsifier chosen from lecithin, mono-, di- or tri-glycerides of aliphatic (optionally acetylated) polycarboxylic acids (eg citric or tartaric acid) or ascorbyl palmitate.

公开(公告)号：AU1620397A

公开(公告)日：1997-09-18

申请号：AU1620397

申请日：1997-03-07

Applicant: BASF AG

Inventor： SCHWEIKERT LONI ,  KOLTER KARL

IPC: A61K9/107 ,  A61K31/01 ,  A61K31/015 ,  A61K31/035 ,  A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K47/10 ,  A61K47/24 ,  A61P3/02 ,  A61P43/00 ,  A61K31/595 ,  A61K35/78 ,  A61K47/12 ,  A61K47/14 ,  A61K47/34 ,  A61K47/44

公开(公告)号：CA2199414A1

公开(公告)日：1997-09-11

申请号：CA2199414

申请日：1997-03-06

Applicant: BASF AG

Inventor： SCHWEIKERT LONI ,  KOLTER KARL

IPC: A61K9/107 ,  A61K31/01 ,  A61K31/015 ,  A61K31/035 ,  A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K47/10 ,  A61K47/24 ,  A61P3/02 ,  A61P43/00

Abstract: A stable oil-in-water emulsion suitable for parenteral administration, containing less than 10% by weight lecithin, consisting of an aqueous phase and of an oil phase which is very finely dispersed by means of a physiologically tolerated emulsifier and which contains at least one carotenoid and is based on a physiologically tolerated oil or fat and comprises as emulsifier polyoxyethylene/polyoxypropylene block polymers and/or lecithin, and wherein the carotenoid is present in the oil phase in a concentration above the saturation solubility of the carotenoid in the oil or fat at room temperature.

公开(公告)号：ES2225593T3

公开(公告)日：2005-03-16

申请号：ES01963002

申请日：2001-09-11

Applicant: BASF AG

Inventor： HASSELWANDER OLIVER ,  KRAEMER KLAUS ,  BALDENIUS KAI-UWE ,  KLATT MARTIN JOCHEN ,  SCHWEIKERT LONI

IPC: A61K31/381 ,  A23L1/30 ,  A61K31/00 ,  A61K31/202 ,  A61K31/385 ,  A61P3/10 ,  A61P9/10 ,  A61P13/12 ,  A61P25/02 ,  A61P27/02

Abstract: Empleo de al menos un ácido lipónico, de un derivado o una sal fisiológicamente aceptable del mismo, y de al menos un compuesto de la fórmula I H3C-(CH2)n1-(CH=CH)n3-(CH2)n2-COOH I en la que n1, n2 significan independientemente entre sí, valores con un número entero desde 3 hasta 9, n3 significa un valor con un número entero desde 2 hasta 6 y el número de los átomos de carbono es 18, 20 o 22, un derivado o sal fisiológicamente aceptable del mismo, para la obtención de agente para el tratamiento de trastornos diabéticos.

公开(公告)号：DK1317264T3

公开(公告)日：2004-11-29

申请号：DK01963002

申请日：2001-09-11

Applicant: BASF AG

Inventor： HASSELWANDER OLIVER ,  BALDENIUS KAI-UWE ,  KRAEMER KLAUS ,  KLATT MARTIN JOCHEN ,  SCHWEIKERT LONI

IPC: A61K31/381 ,  A23L1/30 ,  A61K31/00 ,  A61K31/202 ,  A61K31/385 ,  A61P3/10 ,  A61P9/10 ,  A61P13/12 ,  A61P25/02 ,  A61P27/02

Abstract: The present invention relates to the use of lipoic acid, a physiologically acceptable derivative or salt thereof and one compound of the formula I H3C-(CH2)n1-(CH=CH)n3-(CH2)n2-COOH I in which n1, n2 have, independently of one another, the value of an integer from 3 to 9, n3 has the value of an integer from 2 to 6, and the number of carbon atoms is 18, 20 or 22, a physiologically acceptable derivative or salt thereof, for nutritional supplementation, in functional foods and for therapeutic purposes in the treatment of diabetic disorders. Compositions having a corresponding active ingredient combination, and compositions in the form of commercial packs with corresponding combination products or single-drug products for combined use are also described.

公开(公告)号：DE19951615A1

公开(公告)日：2001-05-03

申请号：DE19951615

申请日：1999-10-26

Applicant: BASF AG

Inventor： RUNGE FRANK ,  SCHWEIKERT LONI

IPC: A23L2/58 ,  A23L2/62 ,  A23L5/44 ,  A23L33/15 ,  C09B61/00 ,  C09K23/00 ,  C09K23/34 ,  B01F17/00 ,  B01F17/34 ,  A23L2/38

Abstract: In the stabilization of a fluid, aqueous preparation, a colloid free stabilizer emulsion is obtained by removing colloid stabilizer with a fat soluble substance, then mixing the emulsion with another aqueous phase. The emulsion comprises 1-50 wt.% fat soluble substance. An Independent claim is included for the stabilized preparation.